News and Announcements
Kazia announces positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma
- Published December 03, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our Chief Executive Officer, Dr James Garner, recently sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.
The interview covers:
- How the data shows a progression free survival in the eight patients treated of around 8.4 months, which compares very favourably to benchmarks for glioblastoma
- How GDC-0084 extended progression free survival of MGMT methylated patients who are resistant to temozolomide, the current standard of care
- How Kazia believes GDC-0084 has every possibility of being the next drug that is FDA approved for glioblastoma
- The $US1.5 billion untapped market opportunity in glioblastoma
- That Kazia is looking to use GDC-0084 in other forms of brain cancer
Watch the video interview here.
Interview with BioWorld
In addition, Dr Garner was also interviewed in BioWorld on the interim efficacy data as well as the overall GDC-0084 program.
In the interview, Dr Garner said that by the standards of drug development, the GDC-0084 program “has moved incredibly fast.”
“In one sense, that’s exactly how it should be for a drug with as terrible a prognosis as glioblastoma,” he added. “But it also reflects what we’ve tried to do in Kazia. Our goal has been to put forward this agile model for drug development, and the GDC-0084 story is a good illustration of exactly what we’ve been trying to do as a company.”
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
